基于雪貂模型的常山碱盐呕吐特点及致吐机制研究
批准号:
82104518
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
马丽娜
依托单位:
学科分类:
中药毒理
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
马丽娜
中文摘要
疟疾是全球关注的重要公共卫生问题之一。近年来随着一线用药青蒿素耐药性的报道越来越多,亟需研发结构迥异的新型抗疟药。常山为传统抗疟良药,其抗疟效价优于氯喹和青蒿素,但囿于其强烈的致吐副作用,严重制约了其在临床的广泛使用。问题的聚焦点在于:(1)缺乏灵敏且关联临床的呕吐评价模型;(2)致吐机制不清。因此,本项目在前期开创性引入评价呕吐作用金标准的雪貂模型的基础上,通过系统评价DAS诱导呕吐作用特点,以Ca2+/CaMKII/ERK1/2介导的5-HT3和NK1受体通路交互作用为切入点,通过正向激活和反向抑制两个角度,共同探究DAS诱导呕吐的关键环节和分子机制。同时通过脑内直接注射阻断剂对DAS诱导的迷走神经放电行为和呕吐现象的影响,探究DAS到底是通过还是外周,中枢还是两者共同作用诱导的呕吐现象。为临床如何针对性的拮抗常山诱导的呕吐副作用提供科学依据。
英文摘要
Malaria is one of the important public health issues of global concern. In recent years, with more and more reports on the resistance of first-line artemisinin, there is an urgent need to develop new antimalarial drugs with very different structures. Changshan is a traditional antimalarial medicine. Its antimalarial potency is superior to chloroquine and artemisinin, but its strong vomiting side effects severely restrict its widespread clinical use. The focus of the problem is: (1) The lack of a sensitive and clinically relevant vomiting evaluation model; (2)Unclear mechanism of vomiting. Therefore, on the premise of solving the sample preparation in the early stage, this project pioneered the introduction of the ferret model for evaluating the vomiting effect gold standard. -The interaction between HT3 and NK1 receptor pathways is the entry point. Through the two angles of positive activation and reverse inhibition, we will jointly explore the key links and molecular mechanisms of DAS-induced vomiting. At the same time, the effect of DAS-induced vagal discharge and vomiting by direct injection of blockers into the brain is explored to determine whether DAS is through or peripheral, central, or both. Provide scientific basis for how to antagonize the side effects of Changshan induced vomiting clinically.
常山为传统抗疟良药,其抗疟效价优于氯喹和青蒿素,但囿于其强烈的致吐副作用,严重制约了其在临床的广泛使用。问题的聚焦点在于:(1)缺乏灵敏且关联临床的呕吐评价模型;(2)呕吐机制不清楚。因此,本项目通过创新性的引入国际公认的呕吐评价金标准-雪貂,发现常山碱盐(DAS)对雪貂的催吐作用非常强大,3 mg/kg已能使全部雪貂发生呕吐,呕吐事件主要发生在药后2 h内,在药后1.5 h达到高峰,明确了DAS急性期呕吐特点;随后采用小鼠毒代动力学和量时毒实验,同时佐以斑马鱼早期安全性评价模型,系统表征了DAS不同给药途径的毒代和组织分布特点,明确了DAS主要毒性靶器官为胃肠道;随后对DAS诱导的胃肠道电生理现象观察,以明确DAS是否有直接外周刺激作用,发现DAS可明显激发离体肠管自主收缩,使肠管平均张力增强,5-HT3R拮抗剂帕拉诺司琼(Pal)和NK1R拮抗剂阿瑞匹坦(Apr)均可有效降低DAS诱导的肠管收缩平均张力,使其浓度效应曲线非平行右移,最大效应显著降低,两者联用可增强协同抑制效应,提示Pal和Apr对于DAS阻断作用可能属于非竞争性拮抗。采用NG108-15神经细胞模型,研究DAS对胞内[Ca2+]i水平影响,结果不同浓度的DAS均可使细胞内[Ca2+]i增加,且呈明显的剂量依赖性。Pal和Apr均可剂量依赖性的抑制DAS诱导的[Ca2+]i增加,再次证明DAS诱导的呕吐作用,可能是通过同时刺激5-HT3R和NK1R通路诱导细胞内[Ca2+]i增加,诱导的呕吐现象。采用原子杂交定位实验,进一步明确DAS对脑部和肠道5-HT3R和NK1R蛋白表达影响,结果发现5-HT3R和NK1R mRNA表达量在脑部随DAS浓度升高均无明显变化,但在胃肠道部位表达有明显增高;而神经递质sp mRNA表达量在脑部和肠道表达量随DAS浓度升高而上升。提示,DAS可激活胃肠道5-HT3受体和NK1受体,刺激肠嗜铬细胞释放SP呕吐神经递质,促进胞内[Ca2+]i内流增加,最终诱发呕吐现象。镇吐剂Pal可有效拮抗DAS诱导的呕吐行为,为临床针对性的拮抗DAS诱导的呕吐副作用提供参考,同时建立的雪貂呕吐模型可为其他类似研究提供借鉴和参考。
国内基金
海外基金